Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.77 |
| ▸ | CSF1R | P07333 | 1/20 | 0.77 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.77 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diaveridine SCHEMBL29527560 | 1.00 | DHFR (1.00) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL10488908 | 0.92 | DHFR (0.85) | DHFRHTTNTRK1CSF1RNTRK3 | |
| Diaveridine SCHEMBL11480370 | 0.91 | DHFR (0.83) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL9830386 | 0.90 | DHFR (0.82) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL10488971 | 0.90 | DHFR (0.81) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL10488965 | 0.89 | DHFR (0.79) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL10488898 | 0.89 | DHFR (0.79) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL9657245 | 0.88 | DHFR (0.78) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL9654048 | 0.88 | DHFR (0.78) | DHFRHTTNTRK1CSF1RNTRK3 | |
| SCHEMBL7126736 | 0.88 | DHFR (0.78) | DHFRHTTNTRK1CSF1RNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1665 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536217-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | Fleurir Abx LLC (US) | 2025-04-16 | — | — | EP | claimed |
| US-20250076282-A1 | Identification of Viable Human Embryos | Overture Life, Inc. (US) | 2025-03-06 | — | — | US | claimed |
| US-12181462-B2 | Identification of viable human embryos | Overture Life, Inc. (US) | 2024-12-31 | — | — | US | claimed |
| US-20240293434-A1 | COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS | FLEURIR ABX LLC (US) | 2024-09-05 | — | — | US | claimed |
| US-20230398101-A1 | Co-agents as Therapy Against Anaerobic Pathogens | FLEURIR ABX LLC (US) | 2023-12-14 | — | — | US | claimed |
| WO-2023239822-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | FLEURIR ABX LLC (US) | 2023-12-14 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3999846-A1 | IDENTIFICATION OF VIABLE HUMAN EMBRYOS | Overture Life, Inc (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| US-6545033-B1 | GABA receptor inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | claimed |
| WO-2002096216-A1 | A METHOD OF IMPROVING THE GROWTH PERFORMANCE OF AN ANIMAL | THE UNIVERSITY OF SYDNEY (AU) | 2002-12-05 | — | — | WO | claimed |
| WO-2002067979-A1 | METHOD OF IMPROVING THE GROWTH PERFORMANCE OF AN ANIMAL | THE UNIVERSITY OF SYDNEY (AU) | 2002-09-06 | — | — | WO | claimed |
| US-6211185-B1 | ADMINISTERING ORALLY WITH DRINKING WATER | VETERINARY PHARMACY CORPORATION | 2001-04-03 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-4873249-A | 2,4-DIAMINO-5-(3,4-DIMETHOXY-BENZYL)-PYRIMIDINE; ANALGESIC OR ANTINFLAMMATORY AGENT | EGIS GYOGYSZERGYAR (HU) | 1989-10-10 | — | — | US | claimed |
| US-4871722-A | TRIMETOPRIM, DIAVERIDINE, SULFADIMETHOXINE, 8-HYDROXYQUINOLINE, AND/OR SALTS; POULTRY; ANTIBACTERIAL FEEDS | EGIS GYOGYSZERGVAR (HU) | 1989-10-03 | — | — | US | claimed |
| US-4133879-A | Process for producing stable solutions of a sulphonamide and a potentiator | AKTIESELSKABET ROSCO (DK) | 1979-01-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293434-A1 | COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS | SLC11A2, MYD88, FPR2 | DHFR 7/4885HTT 2861/4885NTRK1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.